Long non coding mitochondrial RNAs as potential targets for diagnosis and therapy of bladder cancer

Jaime Villegas, Alexis Rivas, Rodolfo Ávila, Vincenzo Borgna, Lorena Lobos-Gonzales, Verónica Burzio, Constanza López, Reynaldo Gomez, Eduardo Landerer, Laura Velarde, L. O. Burzio

Resultado de la investigación: Research - revisión exhaustivaChapter

  • 1 Citas

Resumen

Bladder cancer (BC) is a heterogeneous disease with 70% of patients presenting superficial tumours and 30% presenting muscle-invading disease with a high risk of death associated to metastasis. The diagnosis is carried out by urine cytology, whith high specificity but low sensitivity, and cystoscopy, an expensive and unpleasant procedure. Carcinoma in situ and other high grade non-muscle-invasive tumors are treated by intravesical administration of BCG or other chemotherapeutic agents, while the indication for muscle-invasive disease is radical cystectomy. Human cells express a family of mitochondrial long non-coding RNAs (ncRNAs). One of these transcripts, the sense mitochondrial ncRNA or SncmtRNA, is expressed in normal proliferating cells and tumor cells but not in non-dividing cells. In addition, normal human proliferating cells express two antisense transcripts, ASncmtRNA-1 and ASncmtRNA-2. Strikingly however, the ASncmtRNAs are downregulated in tumor cell lines as well as in tumor cells present in different types of human cancer, including BC. Therefore, the differential expression profile of these transcripts allows to detect cancer cells in biopsies and biological fluids. Down-regulation of the ASncmtRNAs seems to be an important hallmark of cancer and, hypothetically, may also represent a general vulnerability of cancer cells. Indeed, knock-down of the ASncmtRNAs using antisense oligonucleotides (ASO) exerts negative effects on cell proliferation and viability of bladder cancer cell lines representing a novel therapeutic strategy for this disease. We discuss recent advances on the use of the mitochondrial ncRNAs as targets for diagnostic and therapeutic protocols of BC and its potential use in the clinic.

IdiomaEnglish
Título de la publicación alojadaBladder Cancer
EditorialNova Science Publishers, Inc.
Páginas95-116
Número de páginas22
ISBN (versión digital)9781633216709
ISBN (versión impresa)9781633216662
EstadoPublished - 1 ene 2014

Huella dactilar

Long Noncoding RNA
Urinary Bladder Neoplasms
Therapeutics
mitochondrial RNA
Neoplasms
Down-Regulation
Muscles
Intravesical Administration
Untranslated RNA
Cystoscopy
Antisense Oligonucleotides
Cystectomy
Carcinoma in Situ
Mycobacterium bovis
Tumor Cell Line
Cell Biology
Cell Survival
Cell Proliferation
Urine
Neoplasm Metastasis

ASJC Scopus subject areas

  • Medicine(all)

Citar esto

Villegas, J., Rivas, A., Ávila, R., Borgna, V., Lobos-Gonzales, L., Burzio, V., ... Burzio, L. O. (2014). Long non coding mitochondrial RNAs as potential targets for diagnosis and therapy of bladder cancer. En Bladder Cancer (pp. 95-116). Nova Science Publishers, Inc..
Villegas, Jaime ; Rivas, Alexis ; Ávila, Rodolfo ; Borgna, Vincenzo ; Lobos-Gonzales, Lorena ; Burzio, Verónica ; López, Constanza ; Gomez, Reynaldo ; Landerer, Eduardo ; Velarde, Laura ; Burzio, L. O./ Long non coding mitochondrial RNAs as potential targets for diagnosis and therapy of bladder cancer. Bladder Cancer. Nova Science Publishers, Inc., 2014. pp. 95-116
@inbook{54bb151b3e794681baf7e5888ada0724,
title = "Long non coding mitochondrial RNAs as potential targets for diagnosis and therapy of bladder cancer",
abstract = "Bladder cancer (BC) is a heterogeneous disease with 70% of patients presenting superficial tumours and 30% presenting muscle-invading disease with a high risk of death associated to metastasis. The diagnosis is carried out by urine cytology, whith high specificity but low sensitivity, and cystoscopy, an expensive and unpleasant procedure. Carcinoma in situ and other high grade non-muscle-invasive tumors are treated by intravesical administration of BCG or other chemotherapeutic agents, while the indication for muscle-invasive disease is radical cystectomy. Human cells express a family of mitochondrial long non-coding RNAs (ncRNAs). One of these transcripts, the sense mitochondrial ncRNA or SncmtRNA, is expressed in normal proliferating cells and tumor cells but not in non-dividing cells. In addition, normal human proliferating cells express two antisense transcripts, ASncmtRNA-1 and ASncmtRNA-2. Strikingly however, the ASncmtRNAs are downregulated in tumor cell lines as well as in tumor cells present in different types of human cancer, including BC. Therefore, the differential expression profile of these transcripts allows to detect cancer cells in biopsies and biological fluids. Down-regulation of the ASncmtRNAs seems to be an important hallmark of cancer and, hypothetically, may also represent a general vulnerability of cancer cells. Indeed, knock-down of the ASncmtRNAs using antisense oligonucleotides (ASO) exerts negative effects on cell proliferation and viability of bladder cancer cell lines representing a novel therapeutic strategy for this disease. We discuss recent advances on the use of the mitochondrial ncRNAs as targets for diagnostic and therapeutic protocols of BC and its potential use in the clinic.",
author = "Jaime Villegas and Alexis Rivas and Rodolfo Ávila and Vincenzo Borgna and Lorena Lobos-Gonzales and Verónica Burzio and Constanza López and Reynaldo Gomez and Eduardo Landerer and Laura Velarde and Burzio, {L. O.}",
year = "2014",
month = "1",
isbn = "9781633216662",
pages = "95--116",
booktitle = "Bladder Cancer",
publisher = "Nova Science Publishers, Inc.",

}

Villegas, J, Rivas, A, Ávila, R, Borgna, V, Lobos-Gonzales, L, Burzio, V, López, C, Gomez, R, Landerer, E, Velarde, L & Burzio, LO 2014, Long non coding mitochondrial RNAs as potential targets for diagnosis and therapy of bladder cancer. En Bladder Cancer. Nova Science Publishers, Inc., pp. 95-116.

Long non coding mitochondrial RNAs as potential targets for diagnosis and therapy of bladder cancer. / Villegas, Jaime; Rivas, Alexis; Ávila, Rodolfo; Borgna, Vincenzo; Lobos-Gonzales, Lorena; Burzio, Verónica; López, Constanza; Gomez, Reynaldo; Landerer, Eduardo; Velarde, Laura; Burzio, L. O.

Bladder Cancer. Nova Science Publishers, Inc., 2014. p. 95-116.

Resultado de la investigación: Research - revisión exhaustivaChapter

TY - CHAP

T1 - Long non coding mitochondrial RNAs as potential targets for diagnosis and therapy of bladder cancer

AU - Villegas,Jaime

AU - Rivas,Alexis

AU - Ávila,Rodolfo

AU - Borgna,Vincenzo

AU - Lobos-Gonzales,Lorena

AU - Burzio,Verónica

AU - López,Constanza

AU - Gomez,Reynaldo

AU - Landerer,Eduardo

AU - Velarde,Laura

AU - Burzio,L. O.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Bladder cancer (BC) is a heterogeneous disease with 70% of patients presenting superficial tumours and 30% presenting muscle-invading disease with a high risk of death associated to metastasis. The diagnosis is carried out by urine cytology, whith high specificity but low sensitivity, and cystoscopy, an expensive and unpleasant procedure. Carcinoma in situ and other high grade non-muscle-invasive tumors are treated by intravesical administration of BCG or other chemotherapeutic agents, while the indication for muscle-invasive disease is radical cystectomy. Human cells express a family of mitochondrial long non-coding RNAs (ncRNAs). One of these transcripts, the sense mitochondrial ncRNA or SncmtRNA, is expressed in normal proliferating cells and tumor cells but not in non-dividing cells. In addition, normal human proliferating cells express two antisense transcripts, ASncmtRNA-1 and ASncmtRNA-2. Strikingly however, the ASncmtRNAs are downregulated in tumor cell lines as well as in tumor cells present in different types of human cancer, including BC. Therefore, the differential expression profile of these transcripts allows to detect cancer cells in biopsies and biological fluids. Down-regulation of the ASncmtRNAs seems to be an important hallmark of cancer and, hypothetically, may also represent a general vulnerability of cancer cells. Indeed, knock-down of the ASncmtRNAs using antisense oligonucleotides (ASO) exerts negative effects on cell proliferation and viability of bladder cancer cell lines representing a novel therapeutic strategy for this disease. We discuss recent advances on the use of the mitochondrial ncRNAs as targets for diagnostic and therapeutic protocols of BC and its potential use in the clinic.

AB - Bladder cancer (BC) is a heterogeneous disease with 70% of patients presenting superficial tumours and 30% presenting muscle-invading disease with a high risk of death associated to metastasis. The diagnosis is carried out by urine cytology, whith high specificity but low sensitivity, and cystoscopy, an expensive and unpleasant procedure. Carcinoma in situ and other high grade non-muscle-invasive tumors are treated by intravesical administration of BCG or other chemotherapeutic agents, while the indication for muscle-invasive disease is radical cystectomy. Human cells express a family of mitochondrial long non-coding RNAs (ncRNAs). One of these transcripts, the sense mitochondrial ncRNA or SncmtRNA, is expressed in normal proliferating cells and tumor cells but not in non-dividing cells. In addition, normal human proliferating cells express two antisense transcripts, ASncmtRNA-1 and ASncmtRNA-2. Strikingly however, the ASncmtRNAs are downregulated in tumor cell lines as well as in tumor cells present in different types of human cancer, including BC. Therefore, the differential expression profile of these transcripts allows to detect cancer cells in biopsies and biological fluids. Down-regulation of the ASncmtRNAs seems to be an important hallmark of cancer and, hypothetically, may also represent a general vulnerability of cancer cells. Indeed, knock-down of the ASncmtRNAs using antisense oligonucleotides (ASO) exerts negative effects on cell proliferation and viability of bladder cancer cell lines representing a novel therapeutic strategy for this disease. We discuss recent advances on the use of the mitochondrial ncRNAs as targets for diagnostic and therapeutic protocols of BC and its potential use in the clinic.

UR - http://www.scopus.com/inward/record.url?scp=84952785607&partnerID=8YFLogxK

M3 - Chapter

SN - 9781633216662

SP - 95

EP - 116

BT - Bladder Cancer

PB - Nova Science Publishers, Inc.

ER -

Villegas J, Rivas A, Ávila R, Borgna V, Lobos-Gonzales L, Burzio V y otros. Long non coding mitochondrial RNAs as potential targets for diagnosis and therapy of bladder cancer. En Bladder Cancer. Nova Science Publishers, Inc.2014. p. 95-116.